< Back to the list of products
Duramune Puppy DP+C, Lyophilisate and diluent for suspension for injection for dogs.
- Provides protection against today’s most current field isolates of canine parvovirus (CPV-2b), stimulating higher levels of parvovirus SN antibodies. The vaccine also provides protection against canine distemper and canine coronavirus.
- Bioreactor technology for production improves product consistency and helps ensure the Duramune range presents antigenically relevant material in all fractions.
- Duramune is better tolerated than older broad spectrum canine vaccines and its primary vaccination can be completed at 10 weeks of age, facilitating earlier socialization.
Description
Duramune Puppy DP+C is a combination vaccine presented as a lyophilisate and diluent for
suspension for injection for dogs.
Each dose comprises:
| Freeze-dried fraction | |
|---|---|
| Active substances: | Per 1 ml dose |
| Canine distemper virus, strain Onderstepoort | 102.5 to 104.8 TCID50* |
| Canine parvovirus, strain SAH | 104.7 to 106.5 TCID50* |
| *TCID50 = tissue culture 50% infective dose | |
| Liquid diluent fraction | |
| Active substances: | Per 1 ml dose |
| Canine coronavirus, strain TN449 (inactivated) | RP* 1.0-2.0** |
| Adjuvants: | |
| Ethylene/Maleic anhydride (EMA) | 0.01 m |
| Neocryl XK-62 (50% solution) | 0.03 ml |
| * hamster 80% protective dose according to Ph.Eur. ** RP = Relative Potency |
|
INDICATIONS
- For the active immunisation of dogs to prevent mortality and reduce disease caused by canine distemper virus and canine parvovirus;
- To reduce infection at the intestinal level caused by canine coronavirus.
CONTRAINDICATIONS
None.
ADVERSE REACTIONS
Following the first vaccination, up to 80% of puppies develop a small visible swelling
(<2 cm) lasting for generally only two days. Following the second vaccination, occasionally a
small visible swelling (up to 5 cm) may be seen at the injection site, which may last for up to
five days. The swelling may be painful for one to two days.
In most cases these small and transient injection site reactions resolve with no need for
treatment.
Overdose
Some puppies may exhibit a transient lethargy by 4 hours post vaccination but recover by two
days post vaccination. Occasionally a small visible swelling (<5 cm) may be seen at the
injection site, which may last for up to 17 days.
TARGET SPECIES
Dogs.
DOSAGE, ROUTE AND METHOD OF ADMINISTRATION
The vaccine is to be administered by subcutaneous injection to dogs aged 6 weeks and above.
Aseptically reconstitute the contents of the freeze-dried fraction using the liquid vaccine.
Shake well before use. The entire contents of the reconstituted vial should be administered as
a single dose.
Primary Vaccination
Puppies 6-10 weeks of age:
The initial vaccination course consists of two vaccinations. The first vaccination should be
given between 6-8 weeks of age and the second vaccination should be given from 10 weeks of
age.
Puppies of at least 10 weeks of age:
Two vaccinations should be given with an interval of 2-4 weeks between doses.
Booster Vaccination
An annual booster vaccination with one dose of Duramune Puppy DP + C is recommended.
ADVICE ON CORRECT ADMINISTRATION
- Sterile needles and syringes should be used for administration.
- Syringes and needles should not have been sterilised chemically or be above ambient temperature. Do not use chemicals to disinfect or sterilise skin.
- Shake well before use.
- Aseptic precautions should be observed.
- Reconstituted vaccine should be used immediately.
WITHDRAWAL PERIOD
Not applicable.
SHELF LIFE
Shelf-life of the veterinary medicinal products as packaged for sale: 18 months.
Use immediately after reconstitution of the freeze-dried vaccine.
SPECIAL STORAGE PRECAUTIONS
Store and transport refrigerated (+2°C to +8°C).
Do not freeze.
Protect from light.
SPECIAL WARNINGS
Do not use in pregnant or lactating bitches.
No information is available on the safety and efficacy of the concurrent use of this vaccine
with any other. This product should not be used concurrently or simultaneously with any
other immunological product.
Do not mix with any other vaccine or immunological product except the diluent vaccine
supplied.
The live virus strains present in the vaccine may spread to unvaccinated animals, but do not
cause disease.
The efficacy of the CDV and CPV components of the vaccine may be reduced due to
maternal antibody (MDA) interference. However, the vaccine has been proven to be of
benefit against virulent challenge in the presence of maternal antibody levels to CDV and
CPV that are likely to be encountered under field conditions. In situations where higher
MDA levels are expected, the vaccination protocol should be planned accordingly.
Any unused vaccine or waste material should be disposed of in accordance with local
requirements.
OTHER INFORMATION
ATC Code: QI07AH04
Nature and composition of immediate packaging
Freeze-dried Fraction: Vial: Type I (Ph.Eur.) glass. 3 ml capacity
Closure: Type I (Ph.Eur.) grey or red bromobutyl rubber stoppers sealed with aluminium
crimp caps
Liquid diluent Fraction
Vial: High-density polypropylene.
Closure: Chlorobutyl snap-on rubber stoppers with centre hole caps sealed with aluminium
crimp caps.
Contents: 1 ml in a 3 ml injection vial.
Pack sizes: Packs with 10 or 25 x 1 ml doses. Each dose is a combination of one vial of the
freeze-dried fraction and one vial of diluent fraction.
